Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of tenofovir disoproxil and tenofovir alafenamide in order to obtain oral bioavailability.
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
The COMBAT HBV Feasibility Trial
- Conditions
- Hepatitis BVertical Transmission of Infectious Disease
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 560
- Registration Number
- NCT05705427
- Locations
- 🇨🇩
Université Protestant au Congo, Kinshasa, Congo, The Democratic Republic of the
Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B
- Conditions
- Patient SatisfactionDrug AdherenceEfficacy, SelfSafety Issues
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05583006
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients with Chronic HBV Infection
- Conditions
- Safety IssuesChronic Hepatitis BTransplant Recipient
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05410496
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 55
- Registration Number
- NCT04824131
- Locations
- 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇿🇦Ward 21 CRS, Johannesburg, Gauteng, South Africa
🇿🇼Spilhaus CRS, Harare, Zimbabwe
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 9
- Registration Number
- NCT04692077
- Locations
- 🇺🇸
St. Jude Children's Research Hosp. ATN CRS, Memphis, Tennessee, United States
🇺🇸John H. Stroger Jr. Hosp. of Cook County ATN CRS, Chicago, Illinois, United States
🇺🇸The Fenway Institute ATN CRS, Boston, Massachusetts, United States
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Conditions
- TuberculosisHIV Infections
- Interventions
- Drug: Bictegravir (BIC)Drug: Doravirine (DOR)Drug: Tenofovir alafenamide (TAF)Drug: Cabotegravir (CAB)Drug: Atazanavir/ritonavir (ATV/r)Drug: Lopinavir/ritonavir (LPV/r)Drug: Second-Line TB TreatmentDrug: Dolutegravir (DTG)Drug: CobicistatDrug: First-Line TB TreatmentDrug: Darunavir/ritonavir (DRV/r)Drug: Ritonavir
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 325
- Registration Number
- NCT04518228
- Locations
- 🇺🇸
Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States
🇿🇦Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa
HIV Pre-exposure Prophylaxis Implementation Hong Kong Study
- Conditions
- HIV Infections
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 339
- Registration Number
- NCT04367688
- Locations
- ðŸ‡ðŸ‡°
Prince of Wales Hospital, Hong Kong, Hong Kong
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
- Conditions
- HIV-1-infection
- Interventions
- Other: Blood collectionDrug: Tenofovir alafenamide/emtricitabineDrug: Abacavir/lamivudineDrug: Switch
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 25
- Registration Number
- NCT04301661
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
- Conditions
- HIV/AIDS
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 10
- Registration Number
- NCT03917420
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2022-05-03
- Target Recruit Count
- 49
- Registration Number
- NCT03670355
- Locations
- 🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸Alabama CRS, Birmingham, Alabama, United States
🇺🇸University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.